Home Blog Page 1174

Cheche Group Announces Strategic Cooperation with Volkswagen DSSO and Cardif Airstar Insurance to Build Digital Insurance System with Intelligent Pricing Model

BEIJING, Jan. 29, 2026 /PRNewswire/ — Cheche Group Inc. (NASDAQ: CCG) (“Cheche” or the “Company”), China’s leading auto insurance technology platform, today announced that Volkswagen (Anhui) Digital Sales and Services Co., Ltd. (“DSSO”), Beijing Cardif Airstar Property & Casualty Insurance Co., Ltd. (“Cardif Airstar Insurance”), and Cheche Group Inc. held a strategic cooperation signing ceremony on January 29, 2026. They will collaborate to develop digital insurance services for Volkswagen owners and expand into areas such as intelligent pricing, intelligent‑driving insurance, and non‑auto insurance. The partnership aims to establish a digital financial and insurance service system covering the full lifecycle of electric vehicle ownership.

DSSO is a wholly owned subsidiary of Volkswagen (China) Investment Co., Ltd. and a core enterprise within Volkswagen Group’s Intelligent Electric Vehicle Center in Hefei. Cardif Airstar Insurance is a Sino‑foreign joint venture property and casualty insurer, with BNP Paribas Cardif, Volkswagen Financial Services Overseas AG and Xiaomi Corporation as its shareholders. Cheche provides insurance services and digital platforms for DSSO.

Pursuant to the strategy, Volkswagen owners will access services through a unified digital entry point within the automaker’s app across electric vehicle purchase, usage, insurance, and financial service scenarios. Cardif Airstar Insurance will provide insurance product design and underwriting services, while Cheche will deliver one‑stop digital solutions through its embedded insurance SaaS system.

In the field of intelligent pricing, Cheche has established an industry-leading, full‑chain, dynamic data loop. The system integrates driving‑behavior data from intelligent connected vehicles—including rapid acceleration, hard braking, and steering‑angle indicators—together with road‑condition data, in‑vehicle interaction frequency, and industry claims data. This process generates a unique “risk profile” for each Volkswagen owner. With the support of AI‑based pricing and anti‑fraud models, these data points are transformed into precise pricing factors to achieve differentiated premiums under the principle of “better driving, better pricing.”

Cheche’s pricing model also features dynamic learning capabilities. By connecting to automaker’s electric power control systems with insurer direct repair program networks, real‑time claims data flows back into the model for parameter calibration, forming a positive cycle of “risk identification → pricing → claims → optimization.” As cooperation deepens, the partners will extend this intelligent pricing system into intelligent‑driving insurance, helping to address the challenge of liability determination in intelligent‑driving scenarios and to provide a practical reference for industry innovation.

“Today’s signing marks the beginning of a shared vision among all parties. By integrating data, technology, real‑world scenarios, and ecosystem resources, we will deliver a more seamless and intelligent service experience to Volkswagen owners. This cooperation enables us to jointly build solutions that support the full lifecycle of electric vehicle use and achieve meaningful improvements in service quality,” said Mr. Lei Zhang, founder and CEO of Cheche.

The three parties jointly witnessed the signing ceremony and committed to continue collaborating to serve Volkswagen owners, enabling users to benefit from comprehensive solutions built on data, technology, and collaborative ecosystems and experience meaningful improvements in service quality.

Safe Harbor Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding existing and new partnerships and customer relationships, projections, estimation, and forecasts of revenue and other financial and performance metrics, projections of market opportunity and expectations, the Company’s ability to scale and grow its business, the Company’s advantages and expected growth, and its ability to source and retain talent, as applicable. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management, and are not predictions of actual performance. These statements involve risks, uncertainties, and other factors that may cause the Company’s actual results, levels of activity, performance, or achievements to materially differ from those expressed or implied by these forward-looking statements. Further information regarding these and other risks, uncertainties, or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this press release, the Company cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of the Company as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, the Company does not undertake any duty to update these forward-looking statements.

About Cheche Group Inc.

Established in 2014 and headquartered in Beijing, China, Cheche is a leading auto insurance technology platform with a nationwide network of around 108 branches licensed to distribute insurance policies across 25 provinces, autonomous regions, and municipalities in China. Capitalizing on its leading position in auto insurance transaction services, Cheche has evolved into a comprehensive, data-driven technology platform that offers a full suite of services and products for digital insurance transactions and insurance SaaS solutions in China. Learn more at https://www.chechegroup.com/en.

Cheche Group Inc.:

IR@chechegroup.com

Crocker Coulson
crocker.coulson@aummedia.org
(646) 652-7185

Annual Pet Event “Pet Show 2026” Opens Today

Nearly 1,000 Booths Gathered

Ancient Egypt and Mantis-Themed Zones Create a Pet-and-People Carnival

HONG KONG, Jan. 29, 2026 /PRNewswire/ — Organized by Exhibition Group, Hong Kong’s largest public pet exhibition, the “Pet Show 2026” (the Show), opens today through 1 February (Thursday to Sunday) at the Hong Kong Convention and Exhibition Centre. This year’s Show features nearly 1,000 booths, the most world-renowned pet food and supplies brands assembled in Hong Kong and is hailed as the “Brands and Products Expo” of the pet industry. Visitors can enjoy one-stop shopping for pet foods and drinks, apparel, toys, grooming and cleaning products, health supplements and medicines, cages and habitats, and more, meeting the needs of every beloved companion. Multiple themed zones and rich programming invite all pet lovers to attend with their pets and experience the festive atmosphere of the city’s signature annual pet event.

Annual Pet Event “Pet Show 2026” Opens Today.
Annual Pet Event “Pet Show 2026” Opens Today.

The opening ceremony was attended by Dr. Bernard Chan, Under Secretary for Commerce and Economic Development of the Government of the Hong Kong Special Administrative Region, Hon., Dr. Jackie Yip, Assistant Director (Inspection and Quarantine) of the Agriculture, Fisheries and Conservation Department, Mr. SHIU Ka-fai, Member of the CPPCC National Committee and Legislative Council, Ms. Helena Chen, Managing Director of Hong Kong & Macau, Mastercard Worldwide, Ms. Angela Chan, Chairman of Hong Kong Pet Trade Association, Dr. Louis Ng, Museum Director of the Hong Kong Palace Museum, Ms. Phebe Lo, Chairman of Hong Kong Black Cat Club, Mr. Rex Li, Honorary Chairman of Hong Kong Kennel Club, Mr. Kenneth Wong, Development Director of Life-Med Foundation Group Limited, Dr. Sharon Kwok, Ambassador for Endangered Species, and Mr. Carl Wong, Chairman of Exhibition Group.

Mr. Carl Wong, Chairman of Exhibition Group, said: “The global pet industry continues to grow, with the pet food market projected to reach US$134.46 billion in 2026. In Hong Kong, more than 240,000 households keep pets—over 400,000 animals in total—driving substantial related consumption. With the Government actively promoting pet-friendly policies and streamlining quarantine measures, the industry is embracing new opportunities. This year, the Pet Show is partnering for the first time with the Hong Kong Palace Museum to introduce an ‘Ancient Egypt Unveiled’ cultural experience zone, showcasing the profound bond between people and their pets. Looking ahead, we will continue to foster industry exchange and innovation, working together to build a more inclusive, pet-friendly city.”

“Ancient Egypt Unveiled” Special Zone: Giant “Pharaoh Cat” Debuts

For the first time, the Pet Show is collaborating with the Hong Kong Palace Museum to present a special zone themed after the “Ancient Egypt Unveiled: Treasures from Egyptian Museums” exhibition, featuring a 2.5-metre tall “Pharaoh Cat” installation—a must-visit photo spot this year. In ancient Egypt, cats were regarded as sacred animals and symbols of the household protector goddess Bastet. The zone will introduce artefacts related to the cat deity, enabling visitors to learn about the profound connection between ancient Egyptians and cats. Visitors who purchase tickets or memberships on-site will receive a complimentary “Pharaoh Cat” Lucky Charm*. A selection of the beloved ancient Egypt-themed merchandise will also be available, including the Black Cat Plush Collectible, the Pharaoh Pet Beanie, and the Hekha and Nekhakha Pet Teaser Set. Exclusive educational products, including the Ancient Egypt Unveiled: Young Explorer’s Guide picture book, Pyramid Paper Folding Kit, and the catalogue of the special exhibition “Ancient Egypt Unveiled: Treasures from Egypt Museums” will also be available*. Launching simultaneously on-site and across online platforms, the interactive activity “Searching for Pharaoh’s Cat” offers participants the chance to receive an exclusive, non-sale “Pharaoh Cat” Fan* on-site, allowing the public to discover ancient Egyptian culture while enjoying a new experience that blends pets with history.

*Limited quantities; while stocks last.

“Mantis Mania 2: Walking with the Dragons” Returns Multiple Themed Zones Become Photo Hotspots

The popular live mantis exhibition “Mantis Mania 2: Walking with the Dragons” returns with nearly 50 mantis species. This edition adds more than a dozen new species, including the colorful Metal Mantis, Peru’s largest clear‑winged giant mantis, the distinctive South American Rhombodera mantis, the East African Leopard Bullet mantis—resembling bullets and tree bark—and uniquely shaped A‑genus dead‑leaf mantises. To celebrate the upcoming Lunar New Year, the exhibition will feature the “Dragon Mantis,” whose form resembles the Chinese dragon, giving visitors a rare, up‑close look at these fascinating creatures.

This year’s Show also presents key themed zones and photo spots, including “Retro Goldfish Street” and “Mandy Cat Cha Chaan Teng x Mei Lok Store.” “Retro Goldfish Street” revisits Hong Kong’s classic pet culture, telling the history, evolution, and cultural significance of Goldfish Street, and showcases ornamental fish and related products, with knowledge‑sharing on aquatic plant cultivation, aquascaping, and sustainable fish breeding. Designed with retro neon signage and vibrant colors for an immersive experience, the zone also offers a goldfish ornament workshop to enhance interaction and participation. “Mandy Cat Cha Chaan Teng x Mei Lok Store” blends local cha chaan teng and nostalgic corner‑store elements with adorable cat motifs and vintage décor to create a warm, distinctly Hong Kong ambience—one of this year’s must‑visit photo spots.

Highlights and Diverse Pet Products for Every Family

During the Show, a rich lineup of programs will be staged, including a dog show organized by the Hong Kong Kennel Club, the “15th CFA Championship Cat Show” organized by the Hong Kong Black Cat Club, and the “19th Olympets.”

This year’s Pet Show also brings a diverse range of exhibitors catering to different household needs. Joywood Asia Limited (Booth: 1B R70) presents the Momoji series, which weaves Lunar New Year elements—wealth, prosperity, and good fortune—into pet accessories for a festive touch. Sketto Limited (Booth: 1D G38) features the Disney Zootopia series with cute, stylish designs perfect for matching looks with your pet. Baby Galleria HK (Booth: 1D F81) showcases Tavo pet safety capsules, WonderFold foldable strollers, and the Tavo Shell rocker, combining safety, comfort, and aesthetics for travel and home. Futex Corporation Limited (Booth: 1E C37) introduces the EBO Air 2 Plus home companion robot, offering smart monitoring and interactive entertainment to accompany pets and families around the clock. Pet Cubes (HK) Limited (Booth: 1B R08) launches “human‑grade” fresh pet meals inspired by Hong Kong cha chaan teng flavors, including Char Siu for dogs, as well as Singaporean classics such as braised duck rice—healthy and delicious for pets. Art Hunt Ceramic (Booth: 1C M73) invites visitors to craft ceramic art alongside their pets, creating keepsakes of warm shared moments.

Business Exchange to Drive Industry Growth

To recognize outstanding pet brands, the Show will host the “MoCity Favorite Pet Brand Awards 2025” ceremony, honoring brands beloved by the public and setting benchmarks for the industry. The fair also strengthens trade elements: in addition to exhibitors from Chinese Mainland, Korea, and China Taiwan, pet show organizers from Chinese Mainland, Singapore, Indonesia, Japan, and China Taiwan will co-promote the event to attract professional buyers for on-site exchange.

Ticketing and Spending Offers for Extra Fun

To double the excitement for visitors, purchasers of a ticket to either the “Hong Kong Holiday & Travel Expo 2026” or “Pet Show 2026” can buy one physical ticket to the other exhibition at a special price of HK$10 at the on-site ticket counter (regular price HK$30) by presenting the ticket stub—enjoy travel planning and pet fun in one trip. The on-site “Mastercard Scratch Card Lucky Draw” lets customers who spend every HK$500 in a single receipt at designated booths using a Mastercard receive one entry; HK$1,000 earns two entries, and so on, up to 10 entries per receipt. Prizes include round-trip air tickets for two to Tokyo, Seoul, and Taipei, with a total value over HK$150,000 and more than 3,000 prizes available. Participants can redeem scratch cards at the redemption counter for instant results. License numbers: 061009, 061010.

Pet Show 2026

Date

29 January – 1 February 2026 (Thursday to Sunday)

Time

29–31 January (Thu–Sat): 12:00 noon – 9:00 PM

1 February (Sun): 12:00 noon – 8:00 PM

Venue

Hall 1, Hong Kong Convention and Exhibition Centre

Website

https://www.exhibitiongroup.com.hk/exhibitions/petshow2026

 

About Exhibition Group

Exhibition Group Limited is one of Hong Kong’s renowned exhibition companies. Our core team has been assembled since 2003, bringing together a group of innovative, experienced, and professional exhibition talents. As a leading event management company, specializing in the planning and operation of world-class public exhibitions, conferences, and trade fairs, covering a wide range of industries. With years of industry experience, we are committed to the development of exhibition and marketing businesses, gaining a prestigious reputation within the exhibition industry.

Our company organizes a variety of themed exhibitions and marketing projects, which not only receive substantial support from the business community and exhibitors but also effectively attract a large number of public participants. Each event has garnered rave reviews, resulting in a win-win situation for exhibitors in both product promotion and sales. Notable exhibitions include the Pet Show, In-Home Expo, Premium Pet Supplies Expo, Hong Kong Cat Expo, Hong Kong Holiday & Travel Expo, Extracurricular Activities Festival cum Teaching Materials and Supplies Expo, and Hong Kong Outdoor & Sports Expo, among others. In recent years, our company has been honored with several awards, including the “Outstanding Award for Pandemic Resilience,” “ESG Commendation Awards,” and “Innovative Exhibition Planning,” recognizing our business development achievements across various sectors.

This press release is distributed by Market Hubs Holdings Limited.

For Media Enquiry,

Market Hubs Holdings Limited

Lierence Li

Debbie So

+852 3998-4900

+852 3998-4900

lierence@markethubsgroup.com

debbie@markethubsgroup.com

 

 

 

Innovate to Benefit Society: Clarivate validates PolyU’s research excellence–achieving outstanding growth in research output and global leadership in engineering and AI-medical research


HONG KONG SAR – Media OutReach Newswire – 29 January 2026 – The Hong Kong Polytechnic University (PolyU) yesterday unveiled the PolyU Research Excellence Report at a high-profile forum co-hosted with Clarivate, a leading global provider of transformative intelligence. The landmark report provides a comprehensive evaluation of PolyU research achievements and impact, reaffirming the University’s position as a global innovation powerhouse. The event, “Research Excellence Report Launch cum Impact Forum: Innovating for Global Impact”, drew around 100 distinguished attendees, including academic leaders from other tertiary institutions in Hong Kong and the Chinese Mainland, industry partners and policymakers. According to Clarivate, PolyU achieved a remarkable 65% surge in high-impact research output and a 55% rise in highly cited papers from 2020 to 2024, and led all University Grants Committee (UGC)-funded institutions in research publications in 2024, underscoring its position at the forefront of Hong Kong’s academic excellence.

The event was officiated by Prof. Timothy TONG, Chairman of the Research Grants Council (RGC); Mr Osher GILINSKY, Vice President for Asia Pacific, Academia and Government, Clarivate; and Prof. Christopher CHAO, Senior Vice President (Research and Innovation) of PolyU, who delivered opening remarks.

Celebrating PolyU’s exceptional research achievements and their far-reaching impacts on society, the Nation and the world, Prof. Tong stated, “The PolyU Research Excellence Report vividly demonstrates its commitment to sustainable development, reflecting the dedication and innovation of its faculty, researchers and students.” Prof. Tong commended PolyU for its effective use of research resources, noting the significant advancements in AI-driven medical breakthroughs, climate solutions and sustainability. He further emphasised the RGC’s ongoing commitment to supporting research that addresses major societal challenges, exemplified by initiatives such as the Research Impact Fund. Additionally, he reaffirmed the RGC’s partnership with universities in strengthening Hong Kong’s status as a global knowledge hub.

Recognising PolyU’s outstanding global research performance, Mr Gilinsky elaborated, “In recent years, PolyU has demonstrated high research productivity in high quality, driving for high impact for the society. PolyU was granted 1,020 patents between 2020 and 2024, the second highest among UGC-funded universities. To enhance research translation, PolyU has formed partnerships with companies including NVIDIA, Huawei and Alibaba. These achievements illustrate PolyU’s international connectivity, diverse disciplinary strengths and strong culture of research translation. Leveraging its strength with the Chinese Mainland resources, PolyU is also accelerating knowledge transfer and identifying emerging areas for discovery, particularly in AI-powered healthcare, sustainable engineering, advanced manufacturing and smart city development—fields where it aims for global leadership.”

Prof. Chao emphasised, “The report is a testament to years of dedicated effort, groundbreaking innovation and the unwavering commitment of the PolyU academic community. In 2025, we are proud to have 21 PolyU scholars named Highly Cited Researchers by Clarivate, while 428 rank among Stanford University’s World’s Top 2% Most-cited Scientists—placing PolyU second among Hong Kong tertiary institutions. Our Strategic Plan 2025/26 – 2030/31, themed ‘Unite to Meet Challenges, Innovate to Benefit Society,’ will further empower PolyU to deliver even more transformative contributions to society.”

Clarivate has been forging continuous collaborations with numerous institutions, including co-authoring the report series The impact of research undertaken by universities in Hong Kong with UGC in 2022. Produced by Clarivate using authoritative data from the Web of Science, the PolyU Research Excellence Report delivers a comprehensive assessment of the University’s overall research performance and achievements, highlighting PolyU’s global leadership in engineering, advancements in powering medical research with emerging AI technologies, and unique contributions to the hospitality, fashion and textile, design and art disciplines that distinguish the University on the global stage.

PolyU’s strengths are exemplified by its leadership in Hong Kong’s research output growth, achieving the highest number of publications among UGC‑funded universities in 2024. Nearly 40% of its outputs are internationally co-authored, while 27% involve QS Top 50 university partners. The quality and impact of the University’s research output are further evidenced by its strong disciplinary performance. In the QS World University Rankings by Subject 2025, seven PolyU disciplines rank in the global Top 30, while, overall, 26 disciplines are listed among the world’s Top 100, underscoring the breadth and depth of the University’s academic excellence across multiple fields.

Following the report launch, the Impact Forum featured a high-level panel discussion on “Innovations and Challenges in Research Evaluation”. The discussion facilitated insightful exchanges between the panel and attendees on evolving approaches to research assessment, the importance of measuring societal impact and strategies for fostering cross-institutional collaboration.

The PolyU Research Excellence Report is now available on the PolyU website: https://www.polyu.edu.hk/ipao/institutional-performance/research-excellence-report/

Highlights from the report:

  • Engineering Leadership: Ranked 6th globally in Engineering and 2nd in Civil Engineering (Subject Rankings of U.S. News & World Report Best Global Universities Rankings 2025-2026), with research supporting Hong Kong’s Cross Bay Link project and national space missions. PolyU engineering publications grew by 68% between 2020-2024, with 38% of Hong Kong’s engineering publications affiliated with the University in 2024.
  • AI-driven Medical Innovations: 261 patents in Computing and Control solutions, including LungRT Pro (a radiotherapy support system), Scolioscan® (radiation-free scoliosis diagnosis) and STARS (a smartphone-based vision screening tool for children). These life‑changing innovations demonstrate PolyU’s strong interdisciplinary integration across computer science, optometry, biomedical engineering, rehabilitation sciences and nursing.
  • Unique Disciplines: Global top rankings in Hospitality and Tourism Management, and Textile Science and Engineering (1st and 5th respectively in ShanghaiRanking’s Global Ranking of Academic Subjects 2025), as well as Art and Design (22nd in QS World University Rankings by Subject 2025). Groundbreaking work includes smart wearables for stroke patients, AI-powered tourism demand forecasting platforms and sustainable community design projects.
  • Collaborative Impact: Over 600 international collaboration agreements with 390+ institutions across 45 countries and regions, and 3,100+ collaborative projects in the Chinese Mainland. Between 2020 and 2024, nearly 40% of its high-quality research publications were co-authored with international institutions. PolyU Unicorn startups have created over 5,000 international job opportunities and generated significant economic value.

Hashtag: #PolyU #Clarivate #ResearchOutput #AIMedical #Engineering #HongKong

The issuer is solely responsible for the content of this announcement.

Saudi Arabia Unveils Ambitious New Privatization Strategy to Expand Public-Private Partnerships

  • Strategy sets out 220+ new public-private partnerships contracts by 2030
  • Targets initial $64 billion (SAR 240 billion) in direct capex investment
  • Broadens private sector participation across new and existing projects
  • National Privatization Strategy accelerates realization of Saudi Vision 2030 economic diversification goals

RIYADH, Saudi Arabia, Jan. 29, 2026 /PRNewswire/ — The Kingdom of Saudi Arabia has launched a new National Privatization Strategy to significantly expand the role of public-private partnerships (PPPs) in delivering and operating large-scale projects and advancing economic diversification of in line with Saudi Vision 2030.

Led by the National Center for Privatization & PPP (NCP), the Strategy provides unprecedented opportunities for long-term foreign direct investment in initiatives to enhance the quality and efficiency of infrastructure and public services in the Kingdom, strengthen the role of the private sector in sustainable economic development, enable the government to focus on its legislative, regulatory and oversight roles, and enhance fiscal sustainability.

Saudi Minister of Finance and Chairman of the Board of the NCP, His Excellency Mr. Mohammed bin Abdullah Al-Jadaan, stated:
“In the Kingdom, we strive to establish future-ready infrastructure with high quality and efficiency, ensuring that public services delivered to citizens, residents, and visitors are among the best in the world, while strengthening the Kingdom’s position as a global reference in public-private partnerships.”

The National Privatization Strategy aims to increase resident and visitor satisfaction with public services across 18 targeted sectors, create tens of thousands of high-quality jobs, sign more than 220 PPP contracts by 2030, and mobilize over $64 billion (SAR 240 billion) in private capital investments by 2030.

The launch of the Strategy marks the transition from the foundational phase – successfully completed under the 2018 Privatization Program – to a new phase focused on execution and accelerating delivery. The Strategy will open up new sectors for private sector investment locally and internationally, including transport and logistics, water, health and education infrastructure and real estate, enable participation in larger and more complex projects, increase financing opportunities, as well as accelerate new partnerships and reinvestment in mature projects.

The government will seek partners for projects including the Saudi Landbridge linking east and west coasts through Riyadh, several education infrastructure projects, water desalination, treatment and strategic reservoir, as well as international airports.

The Strategy establishes five core programs related to planning, regulation, human capital, awareness and prioritization, to enable and advance the privatization ecosystem. These are supported by 42 executive initiatives to achieve its objectives and contribute to Vision 2030 privatization targets. It also includes an executive program dedicated to identifying and prioritizing privatization opportunities, with more than 145 priority opportunities identified—representing attractive investment prospects for the private sector.

The 2018 Privatization Program has achieved several key milestones, most notably the establishment of the National Center for Privatization & PPP (NCP), the approval of more than 200 projects with estimated total investments of approximately $213 billion, and the signing of nearly 90 contracts, including asset sale and PPP contracts across multiple sectors.

The Program also contributed to strengthening private sector participation, enhancing the operational efficiency of government assets, and advancing the legislative and regulatory environment that supports investment – thereby supporting economic diversification goals and improving the Kingdom’s competitiveness regionally and globally.

For more information contact: James Drewer, Ways, James@ways-sa.com

About the National Center for Privatization & PPP (NCP)

The National Center for Privatization & PPP (NCP) is the driving force behind Saudi Arabia’s Private Sector Participation (PSP) ecosystem. Established in 2017, NCP reports directly to the Council of Economic and Development Affairs and plays a vital role in developing world-class infrastructure and public services, contributing to the Kingdom’s sustainable development goals in line with Saudi Vision 2030.

NCP brings together public and private stakeholders, as well as government decision makers to unlock the full potential of the private sector to participate in privatization and public-private partnership (PPP) projects. This collaborative approach leverages private sector expertise and innovation to successfully deliver impactful PPP projects.

Find out more about the NCP here
https://www.ncp.gov.sa/en  and
https://www.ncp.gov.sa/en/NationalStrategy/Pages/default.aspx

About Vision 2030

Saudi Vision 2030, launched in 2016 by the Saudi Government under the leadership of HRH Crown Prince Mohammed bin Salman, is the Kingdom’s roadmap to modernize its society, economy, and government. It seeks to diversify the economy reducing dependence on oil exports and develop other industries including tourism, mining and finance.

The vision rests on three main pillars: positioning Saudi Arabia the “heart of the Arab and Islamic world”, becoming a global investment powerhouse, and transforming the country into a hub connecting Africa and Eurasia.

 

MicuRx Announces FDA Clearance of IND Application to Proceed to Phase 2a Trial of MRX-5 in Patients with Mycobacterium abscessus Pulmonary Disease

FOSTER CITY, Calif., Jan. 29, 2026 /PRNewswire/ — MicuRx Pharmaceuticals, Inc. (“MicuRx”), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MRX-5, enabling the company to initiate a Phase 2a clinical trial in patients with Mycobacterium abscessus pulmonary disease.

M. abscessus pulmonary disease is a serious and prevalent non-tuberculous mycobacterial (NTM) infection associated with high morbidity, prolonged treatment regimens, and limited effective therapeutic options. Current treatments often require multi-drug combinations over extended periods and are frequently complicated by poor tolerability and suboptimal outcomes.

MRX-5 is a novel oral antibacterial agent designed to target NTM. In preclinical studies, MRX-5 demonstrated potent activity against clinical isolates of M. abscessus, including strains resistant to existing standard-of-care therapies. The compound has also shown favorable pharmacokinetic and safety profiles in nonclinical and clinical studies.

“The FDA’s clearance of our IND for MRX-5 represents an important milestone for MicuRx and for patients suffering from M. abscessus pulmonary disease,” said President of MicuRx Jerry (Zhiyue) Li “This approval allows us to advance MRX-5 into a Phase 2a clinical trial,  which aim to assess its safety, and efficacy in patients with M. abscessus pulmonary disease.”

The Phase 2a trial is a multicenter study in the United States designed to evaluate MRX-5 in adults with confirmed M. abscessus pulmonary disease. The trial is expected to generate important clinical data to inform subsequent development  milestones.

This IND clearance further expands MicuRx’s clinical pipeline of anti-infective drugs, reinforcing the company’s commitment to addressing global challenges posed by antimicrobial resistance and difficult-to-treat bacterial infections.

About MRX-5

MRX-5 is a next-generation antibacterial agent being developed by MicuRx for the treatment of non-tuberculous mycobacterial infections, including M. abscessus. The compound is designed for oral administration and aims to provide a more effective and tolerable treatment option.

FDA granted orphan drug designation to MRX-5 for the treatment of NTM infections in 2024.

About MicuRx

MicuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat serious and drug-resistant bacterial infections. Leveraging deep expertise in medicinal chemistry and anti-infective drug development, MicuRx aims to deliver differentiated therapies to address significant unmet medical needs worldwide.

 

XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision

  • Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery.
  • XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery.
  • Cross-sector discussions emphasized the need for bridging gaps between academic research, industrial development, and clinical applications.

SHANGHAI, Jan. 29, 2026 /PRNewswire/ — Recently, XtalPi, a global leader in AI- and robotics-powered drug discovery, successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery. The event convened leading scientists, biopharma innovators, entrepreneurs, and investors from around the world to explore how emerging technologies are redefining strategies for historically “undruggable” protein targets.

XtalPi successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery
XtalPi successfully concluded its 2026 International Symposium on Molecular Glue Drug Discovery

Molecular glue discovery has long relied on serendipity. In his opening remarks, XtalPi Co-founder and CEO Dr. Jian Ma emphasized the need for a fundamental paradigm shift—moving from chance-based discoveries toward a systematic, technology-driven approach enabled by AI, robotics, and global collaboration.

Anchoring this transition, XtalPi Vice President Dr. Yang Xie introduced the company’s proprietary XGlue™ platform. XGlue™ integrates physics-based AI modeling to interrogate complex protein–protein interactions with an agentic AI–controlled autonomous synthesis workflow. This closed-loop design–make–test system enables rapid iteration and significantly expands the addressable target space for molecular glue therapeutics, positioning XtalPi at the forefront of next-generation protein degradation.

The symposium featured a series of scientific presentations highlighting the evolution of the field. Prof. Nathanael S. Gray (Stanford University) and Prof. Bruno Correia (EPFL) discussed leveraging chemically induced proximity and computational de novo design to uncover functional interactions beyond the reach of traditional drug discovery. Prof. Ke Ding (Chinese Academy of Sciences) and Dr. Yong Cang (ShanghaiTech University) presented compelling examples of rationally discovered and designed molecular glues addressing critical diseases with significant unmet medical need. Dr. Jianwei Che (Dana-Farber Cancer Institute) and Dr. Liqiang Fu (GluBio) further highlighted how AI-driven methodologies and enabling technologies are improving target selectivity, enhancing molecular potency, and strengthening the safety profile of glue-based therapeutics. From an investment and commercialization perspective, Mr. Peter Zhang (YAFO Capital) outlined strategic pathways for scaling molecular glue therapies across global markets.

The symposium concluded with a cross-sector roundtable on building a sustainable innovation ecosystem for protein degradation. Moderated by Dr. Yang Xie, the discussion brought together leaders from Sanofi, Betta Pharma, GluBio, and other organizations to address the critical gaps between academic discovery, industrial development, and clinical translation. A shared consensus emerged: sustained progress in protein degradation will require deep integration across science, industry, and capital.

As molecular glue therapeutics continue to gain momentum, the convergence of predictive AI and high-throughput automation is accelerating a shift toward logic-driven drug discovery—transforming once-intractable biological targets into viable therapeutic opportunities.

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

Spectrum Dynamics Medical Receives FDA 510(k) Clearance for Veritas.AI™, Its AI-Powered Noise Reduction Platform for VERITON-CT

SARASOTA, Fla., Jan. 29, 2026 /PRNewswire/ — Spectrum Dynamics Medical, a global leader in digital nuclear medicine imaging solutions, today announced that it has received FDA 510(k) clearance for Veritas.AI™ Noise Reduction, its advanced artificial intelligence platform designed to significantly enhance image quality, diagnostic confidence, and operational efficiency on the VERITON-CT® digital SPECT/CT system.

Veritas.AI represents a major advancement in molecular imaging, leveraging a deep learning convolutional neural network (CNN) to intelligently reduce image noise while preserving the highest spatial resolution and quantitative accuracy. The technology is clinically validated across multiple applications and tracers, including bone imaging, Lu-177 theranostics, and I-123 MIBG, addressing some of the most demanding imaging scenarios in nuclear medicine.

Veritas.AI decreases the scanning times by up to 50% and improves image quality in low-count and high-noise conditions. Veritas.AI enables clinicians to maintain diagnostic accuracy while improving patient comfort and increasing department throughput. Unlike conventional denoising techniques, Veritas.AI performs seamlessly across a wide range of imaging conditions, from routine diagnostic scans to delayed post-therapy imaging.

The Veritas.AI Noise Reduction suite includes dedicated applications optimized for specific clinical needs:

  • Bone-IQ.AI, enabling up to 50% reduction in scan time for whole-body bone imaging while maintaining image quality and enabling throughput of 2–3 patients per hour.
  • Thera-IQ.AI, purpose-built for Lu-177 theranostics, improving post-treatment image quantitative accuracy, and harmonizing noise across time points, which may enhance the accuracy of dosimetry and improve lesion detectability.
  • MIBG-IQ.AI, designed for I-123 MIBG imaging, enabling up to 50% reduction in scan time, delivering safer, faster, and more comfortable exams for children.

When combined with the VERITON-CT’s 360° CZT digital detector architecture, wide-bore design, and quantitation-ready workflows, Veritas.AI further strengthens Spectrum Dynamics’ leadership in digital SPECT/CT imaging—supporting routine clinical practice, advanced theranostics, and clinical research.

“Receiving FDA clearance for Veritas.AI is a significant milestone for Spectrum Dynamics and for the nuclear medicine community,” said Tomer Gabay, Chief Executive Officer of Spectrum Dynamics Medical. “As innovation leaders, we are incredibly excited to bring this powerful AI innovation solution to our customers. Veritas.AI strengthens our commitment to precision imaging by delivering clearer images, greater clinical confidence, and more efficient workflows, while helping hospitals prepare for the rapid growth of theranostics and quantitative SPECT/CT.”

This FDA clearance underscores Spectrum Dynamics’ continued investment in AI-driven innovation, setting a new standard for clarity, confidence, and clinical value in nuclear medicine.

About Spectrum Dynamics Medical

Spectrum Dynamics is spearheading the transformation of SPECT imaging systems from analog to digital detection technology, enabling hospitals and clinicians to provide healthcare services with improved image quality, efficiency and access to advanced clinical applications. Spectrum Dynamics launched the world first digital cardiac SPECT system, the D-SPECT CARDIO – in 2007. Since then, the D-SPECT has become the system of choice for functional cardiac imaging with hundreds of systems sold worldwide. In 2018, Spectrum Dynamics launched its multipurpose SPECT and SPECT-CT systems – the VERITON® and the VERITON-CT® SPECT/CT, first ring-shaped gantry 360 CZT digital SPECT/CT scanner.

For more information, visit www.spectrum-dynamics.com

Papablic Launches SafeguardPlus™ Baby Bottle Washer, the World’s First with built-in Water Purification to Remove Lead and Soften Water

NEW YORK, Jan. 29, 2026 /PRNewswire/ — Papablic, a brand trusted by over 4.5 million parents worldwide, announced the launch of the SafeguardPlus™ Baby Feeding Essentials Cleaning System, the industry’s first and only feeding cleaning system with a built-in water purification system designed to remove lead and soften tap water before cleaning begins.

Innovate to Set a Higher Bar on Baby Feeding Hygiene and Safety

The Papablic SafeguardPlus™ Cleaning System marks a major breakthrough in baby feeding hygiene and safety. Unlike conventional solutions that rely on untreated tap water, Papablic’s newest innovation addresses an often-overlooked risk in baby feeding: water quality itself.

Parents do everything right to keep baby feeding clean. However, analysis of the U.S. Environmental Protection Agency (EPA) lead testing data shows that systems serving about 81% of the U.S. population have detected lead at or above 1 part per billion (the American Academy of Pediatrics’ recommended level for children), and 23.5% of systems have recorded health-based lead violations.

Lead exposure is particularly harmful to infants and children under six because their developing bodies are highly sensitive. Even low levels of lead exposure can cause slowed growth and development mentally and physically.

Papablic SafeguardPlus™ Cleaning System removes avoidable risks at the source by purifying water before cleaning begins.

Deep Clean—From What You See to What You Can’t.

With its pioneering PurifyClean™ Technology, Papablic is redefining what “deep clean” truly means—eliminating visible milk residues and invisible harmful contaminants like lead. Unlike traditional solutions that focus on mechanical cleaning alone, SafeguardPlus™ is designed as a complete feeding hygiene system— addresses both visible and invisible risks from the very first step.

“For SafeguardPlus™ Cleaning System, we didn’t just optimize the cleaning performance—we addressed the part that no one else was controlling : the water itself,” said a Papablic spokesperson. “Our goal is simple — to do it right and take no risks when it comes to baby feeding safety and health. That’s how we safeguard babies and support parents in feeding with greater confidence and ease, by knowing every step is safer by design.”

Key Benefits of Papablic SafeguardPlus™ Cleaning System:

  • Built-in Water Purification System: Removes pontentially harmful contaminants such as lead and softens water within one minute for safer, residue-free cleaning. No distilled or bottled water needed.
  • 8-Bottle Capacity: Cleans up to 8 bottles and other feeding accessories in a single cycle, designed for the multiple daily feeds of newborn and multi-child families.
  • 360° Deep Clean with Faster Cycle: A 5-in-1 automated system that filters, washes, sterilizes, dries, and stores feeding essentials, reducing daily cleaning time up to 30% compared with other solutions.
  • Helps Reduce Up to 99.999% Harmful Germs: Reduce harmful germs and prevent cross-infection while remaining safe for feeding essentials.
  • 100% Baby Safe: Made with certified baby-safe, BPA-free materials.

With the launch of SafeguardPlus™ Cleaning System, Papablic establishes a new benchmark in baby feeding hygiene and safety—where real deep clean starts with safer water, safeguarding every feed from the very first sip.

About Papablic

Founded in 2017, Papablic was born from a vision to create better possibilities for modern parenting. Since day one, Papablic has been dedicated to developing innovative and reliable products that support every parent in their daily feeding routines. Known for its best-selling sterilizer and bottle washer, Papablic prioritizes safety and delivers reliable solutions designed to help parents reclaim time, confidence, and freedom. Loved by over 4.5 million families, Papablic’s parent-centric products have been featured in popular media outlets such as Babylist, The Bump, and Parents. Originally founded by a papa, Papablic aims to help all parents and caregivers enjoy better parenthood with safer and simpler solutions.

For more information, visit https://papablic.com.

New Launch Event Page:https://papablic.com/products/papablic-safeguardplus%E2%84%A2-baby-bottle-washer-system